Clinical Takeaway
In this phase 3 trial of 820 adults, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks for chronic low back pain, with longer-term follow-up extending to one year. The trial used a rigorous randomized, placebo-controlled design across multiple centers, providing high-quality evidence on both efficacy and safety in this large patient population. Chronic low back pain affects over half a billion people globally, and this study represents one of the most substantial clinical investigations of a cannabis-based treatment for this condition to date.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based therapy in chronic low back pain, a prevalent condition where current pharmacologic options demonstrate inadequate efficacy and pose significant safety concerns including opioid-related risks. The large sample size and rigorous trial design establish whether full-spectrum cannabis extract offers a viable, evidence-supported alternative to conventional treatments with potentially improved safety profiles. If efficacy is demonstrated, these findings could inform clinical guidelines for managing CLBP and provide patients with a non-opioid therapeutic option backed by phase 3 evidence.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔙 This phase 3 trial adds meaningful data to the cannabis-for-pain literature by demonstrating efficacy of a full-spectrum extract in chronic low back pain, a condition where current pharmaceutical options remain suboptimal. However, clinicians should note several important caveats: the study population characteristics, baseline pain severity, and concurrent use of other analgesics or physical therapies are not detailed in the abstract, making it difficult to assess generalizability to specific patient populations in typical practice settings. The mechanism by which VER-01 provides analgesia—whether through cannabinoid receptor activation, anti-inflammatory effects, or other pathways—remains incompletely characterized, which limits our ability to predict which patients might benefit most or how it might interact with concurrent treatments. Given the 12-week primary endpoint and 6-month open-label extension, longer-term safety and efficacy data would strengthen clinical confidence. Until full results are published, practitioners considering cannabis extracts for CLBP should use this trial as supporting evidence for